The 1 July 2015 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. The Schedule includes the following new/revised entries:

• Crizotinib (Xalkori) - new listing
• Dapagliflozin propanediol monohydrate (Forxiga) - new indication
• Glycomacropeptide with essential amino acids and vitamins and minerals (PKU Glytactin RTD10, PKU Glytactin RTD15) - new combination product
• Pertuzumab (Perjeta) - new listing
• Ranibizumab (Lucentis) - new indication (diabetic macular oedema)
• Ranibizumab (Lucentis) - new indication (retinal vein occlusion)
• Trastuzumab (Herceptin) - new indications (breast cancer)
• Trastuzumab emtansine (Kadcyla) - new listing

For more details, go to: http://www.pbs.gov.au/browse/changes